← All stocks

BELITE BIO, INC

BLTE Net selling

CIK 0001889109 #1178 in the set updated 17 Sep 2026

Bought (120 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$40.54M

$37.68M on a plan · $0.00 straight out of an exercise

Sold at will

$2.86M

13 of 167 sales

Net

−$40.54M

−$2.86M against sales at will

By person

5 insiders · 167 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Lin Yu-Hsin

Chief Executive Officer

—

$20.82M (25) scheduled

−$20.82M

253,083

$50.12M

−28.3%

Chuang Hao-Yuan

Chief Financial Officer

—

$14.00M (25) scheduled

−$14.00M

231,302

$45.81M

−21.7%

Scholl Hendrik Peter

Chief Medical Officer

—

$2.86M (13)

−$2.86M

15,000

$2.97M

−57.1%

MATA NATHAN L.

Chief Scientific Officer

—

$2.67M (103) scheduled

−$2.67M

$0.00

−100.0%

Chen Wan-Shan

Director

—

$198.47K (1) scheduled

−$198.47K

9,096

$1.80M

−10.8%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 33

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 154

Sales straight out of an exercise 0

Sales at will 13

Transactions with no price 0

Shares from compensation/vesting 20,000

History held since 2 Apr 2026